Strides Pharma,obtained an Establishment Examination Report (EIR) from the US Food and Drug Administration (US FDA) for their Puducherry manufacturing facility. The facility has been reclassified by the USFDA as Voluntary Action Indicated (VAI) from Official Action Indicated (OAI).

In May 2019, the US FDA designated the Strides Puducherry facility as having an OAI, and in July 2019, it sent out a warning notice. The factory provides final dosage formulation products across several dose formats for the US, foreign regulated markets, and institutional businesses. The filed Abbreviated New Drug Applications (ANDAs) from this facility will now begin getting approvals as a result of the US FDA's reclassification.

A strategic agreement between Strides Pharma and Orbicular Pharmaceutical Technologies, a specialised pharmaceutical firm, was launched in order to develop, produce, and distribute nasal sprays for the international markets. At the company's cutting-edge Chestnut Ridge, New York plant, the goods will be produced. Four nasal sprays with a total Global IQVIA market value of more than $400 million will be commercialised under the agreement.

On May 25, Strides is anticipated to release its fourth quarter financial results. The stock has increased by more than 25% over the past year and will increase by around 3% in 2023. On the exchanges, the stock is now trading unchanged.